30
Participants
Start Date
April 20, 2022
Primary Completion Date
April 20, 2026
Study Completion Date
April 20, 2026
PLD Chemotherapy
PLD chemotherapy will be administered 40 mg/m2 as intravenous injection once per cycle.
CDX-1140
CDX-1140 will be administered 1.5mg/kg as intravenous injection once per cycle.
CDX-301
CDX-301 will be administered 75µg/kg as subcutaneous injection daily x 5 doses per cycle for 2 cycles.
RECRUITING
Johns Hopkins University, Baltimore
RECRUITING
University of North Carolina, Chapel Hill
WITHDRAWN
Sarah Cannon Research Institute, Nashville
RECRUITING
University of Chicago Comprehensive Cancer Center, Chicago
ACTIVE_NOT_RECRUITING
Texas Oncology, P.A., Dallas
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
The University of Texas Health Science Center at San Antonio, San Antonio
Collaborators (1)
Celldex Therapeutics
INDUSTRY
Gateway for Cancer Research
OTHER
National Institutes of Health (NIH)
NIH
University of Texas Southwestern Medical Center
OTHER